In 2023, Werewolf Therapeutics, Inc. anticipated multiple catalysts as the company progress the company's two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in fourth quarter of 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.89 USD | -2.20% | +0.82% | +26.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.68% | 212M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.55% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+25.72% | 12.26B | |
+27.17% | 12.05B |
- Stock Market
- Equities
- HOWL Stock
- News Werewolf Therapeutics, Inc.
- Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330